Avrobio Inc. (AVRO) PT Raised to $36 at Wedbush
- Wall St lackluster ahead of Easter break, eyes sharp Q1 gains
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Timken (TKR) Appoints Tarak Mehta as New CEO
AVROBIO, Inc (AVRO) Prices 4.35M Share Common Offering at $23/Sh
February 13, 2020 5:47 AM ESTAVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 4,350,000 shares of its common stock at a public offering price of $23.00 per share. Gross proceeds from the underwritten public offering will total approximately $100 million, before deducting underwriting discounts and commissions and other... More
Avrobio Inc. (AVRO) PT Raised to $35 at Mizuho Securities
February 11, 2020 6:37 AM ESTMizuho Securities analyst Difei Yang raised the price target on Avrobio Inc. (NASDAQ: AVRO) to $35.00 (from $28.00) while maintaining a Buy rating.... More